Erythropoietin - Albumin Platelet-rich Fibrin in Transcrestal Sinus Lifting With Simultaneous Implant Placement
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Erythropoietin and albumin PRF gel + implant placement, Albumin PRF gel +implant placement.
- Who it may be relevant to
- Registry conditions: Sinus Lifting. Basic parameters: 20 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison Between Erythropoietin-enhanced Albumin Platelet-rich Fibrin and Albumin Platelet-rich Fibrin in Transcrestal Sinus Lifting With Simultaneous Implant Placement
Overview
Background: Dental implant therapy in the posterior maxilla may be difficult owing to limited bone height after dental extraction with sinus pneumatization. Several approaches for sinus floor elevation have been documented, and hence trans crestal sinus lifting with albumin platelet rich plasma. Aim of the study: To compare between erythropoietin and albumin platelet rich fibrin transcrestal sinus lifting versus albumin platelet rich fibrin transcrestal sinus lifting using piezoelectric device in patients with atrophic maxilla. Methods: This study will be carried out as a randomized
Interventions
- Other Erythropoietin and albumin PRF gel + implant placement
This group will be treated by transcrestal sinus lifting with erythropoietin and albumin PRF gel with simultaneous implant placement. - Other Albumin PRF gel +implant placement
This group (the Control group) will be treated with transcrestal sinus lifting using albumin PRF gel, with simultaneous implant placement.
Primary outcome measures
- Change in pain scores [Time frame: up to 14 days]
- Change in edema [Time frame: up to 14 days]
- Change in implant stability [Time frame: immediate and 4 months]
Secondary outcome measures (2)
- Change in bone gain [Time frame: baseline and 4 months]
- Change in bone density [Time frame: baseline and 4 months]
Eligibility criteria
Inclusion criteria
- Residual bone height not less than 5 mm measured from crestal bone to sinus floor.
- Both genders.
- Good oral hygiene
- No previous surgery or radiation treatment on the maxillary sinus
Exclusion criteria
- Recent radiation therapy in maxilla.
- Uncontrolled systemic diseases such as diabetes mellitus.
- Heavy smoker (those who smoke ≥ 25 cigarettes a day).
- Alcohol abuse.
- Patient on anticoagulant drug
- Severe allergic rhinitis.
- Tumor or large cyst in the maxillary sinus.
- Oroantral fistula.
- Presence of acute or chronic sinus pathoses or sinus membrane perforation.(
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alex — Alexandria
Identifiers
NCT: NCT07150858 · 1073-5/2025